Literature DB >> 171060

The inhibition of ribosomal RNA synthesis and maturation in Novikoff hepatoma cells by 5-fluorouridine.

D S Wilkinson, T D Tlsty, R J Hanas.   

Abstract

The inhibition of ribosomal RNA (rRNA) maturation by 5-fluorouridine (FUrd) in Novikoff hepatoma cells appears to depend upon the incorporation of the analog into the 45 S rRNA precursor. Precursor synthesized in the presence of FUrd is not processed into mature rRNA, but precursor synthesized in the absence of the analog is processed normally after the addition of the drug. The effect of FUrd on rRNA maturation is concentration dependent. At a concentration of 1 X 10(-4)M, the analog completely inhibits the formation of mature 18 S and 28 S rRNA; while at a concentration of 1 X 10(-7)M, the analog has no significant effect on rRNA maturation. These results suggest that some minimum degree of analog substitution is necessary to inhibit the maturation process. In addition to its inhibition of maturation, FUrd also inhibits the transcription of 45 S rRNA precursor. However, this effect of the drug is less complete and more time dependent that the effect on maturation. The inhibition of rRNA maturation by FUrd persists after removal of the analog from the culture medium. Cells that had been exposed to FUrd for 2 hr were unable to process 45 S rRNA precursor 20 hr after removal of the drug from the medium.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 171060

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  22 in total

1.  Evidence of p53-dependent cross-talk between ribosome biogenesis and the cell cycle: effects of nucleolar protein Bop1 on G(1)/S transition.

Authors:  D G Pestov; Z Strezoska; L F Lau
Journal:  Mol Cell Biol       Date:  2001-07       Impact factor: 4.272

2.  Transcriptional effects of 5-bromo-2'-deoxyuridine in post-implantation mouse embryos.

Authors:  T Palayoor
Journal:  Experientia       Date:  1977-04-15

3.  The effect of structural modifications of 5-fluorouracil derivatives on their transport and biodegradation by isolated rat jejunum.

Authors:  L Novotný; H Farghali; I Janků; J Beránek
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

4.  Regional chemotherapy for colorectal hepatic metastases: evidence for improved survival with new drug combinations.

Authors:  E Sutanto-Ward; Y Arisawa; S Tremiterra; E R Sigurdson
Journal:  Ann Surg Oncol       Date:  1996-01       Impact factor: 5.344

5.  The inhibitory effects of 5-fluorouracil on the metabolism of preribosomal and ribosomal RNA in L-1210 cells in vitro.

Authors:  R Kanamaru; H Kakuta; T Sato; C Ishioka; A Wakui
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

6.  In vitro splicing of pre-messenger RNA with extracts from 5-fluorouridine-treated cells.

Authors:  J R Patton
Journal:  Biochem J       Date:  1994-01-15       Impact factor: 3.857

7.  Balanced production of ribosome components is required for proper G1/S transition in Saccharomyces cerevisiae.

Authors:  Fernando Gómez-Herreros; Olga Rodríguez-Galán; Macarena Morillo-Huesca; Douglas Maya; María Arista-Romero; Jesús de la Cruz; Sebastián Chávez; Mari Cruz Muñoz-Centeno
Journal:  J Biol Chem       Date:  2013-09-16       Impact factor: 5.157

8.  Uridine kinase activities and pyrimidine nucleoside phosphorylation in fluoropyrimidine-sensitive and -resistant cell lines of the Novikoff hepatoma.

Authors:  N Greenberg; D E Schumm; T E Webb
Journal:  Biochem J       Date:  1977-05-15       Impact factor: 3.857

9.  Antitumor activity of FTC-092, a masked 5-trifluoromethyl-2'-deoxyuridine derivative.

Authors:  S Takeda; J Yamashita; H Saito; J Uchida; H Satake; Y Yamada; N Unemi; Y Wataya; H Hayatsu
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

10.  5-Fluorouracil's cytotoxicity is enhanced both in vitro and in vivo by concomitant treatment with hyperthermia and dipyridamole.

Authors:  Y Maehara; Y Sakaguchi; I Takahashi; M Yoshida; H Kusumoto; H Masuda; K Sugimachi
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.